ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CCEL vs JNJ // GROSS PROFIT MARGIN

Cryo-Cell International Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: CCEL 3 — JNJ 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CCEL VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CCEL JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — 67.90% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 18.20% 25.50% -7.30 JNJ /roic <GO>
EV/EBITDA & P/E Valuation 61.2x 18.5x +42.70 JNJ /valuation <GO>
Free Cash Flow Yield 12.55% 2.97% +9.58 CCEL /fcf-yield <GO>
Operating Margin — 34.70% — TIE /operating-margins <GO>
Net Profit Margin — 28.50% — TIE /net-margins <GO>
Revenue Growth (YoY) — 6.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 7.73% 0.00% +7.73 CCEL /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.59 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 8/9 -5.00 JNJ /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 64.3 62.1 +2.18 CCEL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 23.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $41.8M $662.49B -$662.45B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CCEL REV JNJ REV CCEL GROSS % JNJ GROSS % CCEL FCF JNJ FCF
FY 2025 $0 $94.19B — 67.9% $5.2M $19.70B
FY 2024 $0 $88.82B — 69.1% $3.6M $19.84B
FY 2023 $0 $85.16B — — $8.9M $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CCEL // BETA —
JNJ // BETA 1.08